BIOA · Bioage Labs, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Revenue | $2.77M | - | $2.05M | $0 | $1.45M | - | - |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| R&D | $20.41M | - | $18.51M | $10.47M | $9.32M | - | $6.53M |
| SG&A | $7.74M | - | $6.68M | $4.80M | $3.49M | - | $4.73M |
| Total Operating Expenses | $28.15M | - | $25.19M | $15.27M | $12.81M | - | $24.75M |
| D&A | - | - | - | - | - | - | - |
| Operating Income | ($25.38M) | - | ($23.14M) | ($15.27M) | ($12.81M) | - | ($24.75M) |
| Interest Expense | $39.0K | - | $149.0K | $443.0K | $1.22M | - | $388.0K |
| Income Tax | - | - | - | - | - | - | - |
| Net Income | ($22.25M) | - | ($20.17M) | ($21.56M) | ($12.93M) | - | ($23.41M) |
| EPS - Basic | ($0.52) | - | ($0.56) | ($0.60) | ($7.76) | - | ($6.70) |
| EPS - Diluted | ($0.52) | - | ($0.56) | ($0.60) | ($7.76) | - | ($8.74) |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $241.78M | $188.89M | $215.57M | $220.33M | $257.49M | $354.35M | $334.47M |
| Accounts Receivable | $709.0K | $769.0K | $515.0K | $0 | $361.0K | - | - |
| Inventory | - | - | - | - | - | - | - |
| Accounts Payable | $3.07M | $2.67M | $5.02M | $1.33M | $3.99M | $2.00M | $2.10M |
| Current Assets | $391.86M | $286.79M | $290.83M | $301.70M | $324.81M | $357.10M | $336.47M |
| Total Assets | $397.65M | $294.89M | $305.09M | $322.15M | $343.84M | $358.23M | $337.38M |
| Current Liabilities | $15.83M | $20.14M | $24.49M | $22.84M | $23.74M | $27.77M | $19.08M |
| Long-term Debt | - | $0 | $0 | $0 | $1.06M | $2.50M | $8.20M |
| Total Liabilities | $18.53M | $22.84M | $27.63M | $27.37M | $30.67M | $35.11M | $66.60M |
| Stockholders' Equity | $379.12M | $272.05M | $277.46M | $294.78M | $313.17M | $323.13M | ($153.14M) |
| Retained Earnings | ($355.67M) | ($333.42M) | ($307.47M) | ($287.30M) | ($265.74M) | ($252.81M) | ($181.70M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($24.05M) | - | - | - | ($15.67M) | - | - |
| Investing Cash Flow | ($46.75M) | - | - | - | $0 | - | - |
| Financing Cash Flow | $123.72M | - | - | - | $168.00M | - | - |
| CapEx | $26.0K | - | - | - | $0 | - | - |
| Free Cash Flow | ($24.07M) | - | - | - | ($15.67M) | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross margin | - | - | - | - | - | - | - |
| Operating margin | -915.4% | - | -1126.6% | - | -883.0% | - | - |
| EBITDA margin | - | - | - | - | - | - | - |
| Net margin | -802.8% | - | -982.0% | - | -891.0% | - | - |
| Free cash flow margin | -868.4% | - | - | - | -1080.1% | - | - |
| FCF / Net income | 1.08 | - | - | - | 1.21 | - | - |
| R&D / Revenue | 736.3% | - | 901.3% | - | 642.4% | - | - |
| SG&A / Revenue | 279.1% | - | 325.3% | - | 240.7% | - | - |
| Effective tax rate | - | - | - | - | - | - | - |
| Return on assets | -5.6% | - | -6.6% | -6.7% | -3.8% | - | -6.9% |
| Return on equity | -5.9% | - | -7.3% | -7.3% | -4.1% | - | 15.3% |
| Return on invested capital | - | - | - | - | - | - | - |
| Liquidity | |||||||
| Current ratio | 24.76 | 14.24 | 11.87 | 13.21 | 13.68 | 12.86 | 17.63 |
| Quick ratio | 24.76 | 14.24 | 11.87 | 13.21 | 13.68 | 12.86 | 17.63 |
| Cash ratio | 15.28 | 9.38 | 8.80 | 9.65 | 10.85 | 12.76 | 17.53 |
| Leverage | |||||||
| Debt / Equity | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | -0.05 |
| Debt / Assets | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Interest coverage | -650.6x | - | -155.3x | -34.5x | -10.5x | - | -63.8x |
| Equity multiplier | 1.05 | 1.08 | 1.10 | 1.09 | 1.10 | 1.11 | -2.20 |
| Liabilities / Assets | 0.05 | 0.08 | 0.09 | 0.08 | 0.09 | 0.10 | 0.20 |
| Efficiency | |||||||
| Asset turnover | 0.01 | - | 0.01 | 0.00 | 0.00 | - | - |
| Inventory turnover | - | - | - | - | - | - | - |
| Days sales outstanding | 93d | - | 92d | - | 91d | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - |
| Valuation | |||||||
| P / E | - | - | - | - | - | - | - |
| P / B | 2.0x | - | 0.8x | 0.0x | 0.0x | - | - |
| P / S | 268.0x | - | 102.6x | - | 4.3x | - | - |
| EV / EBITDA | - | - | - | - | - | - | - |
| Growth | |||||||
| Revenue growth (YoY) | 91.0% | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -98.0% | - | 6.5% | - | - | - | - |
| Net income growth (YoY) | -72.1% | - | 13.8% | - | - | - | - |
| EPS growth (YoY) | 93.3% | - | 93.6% | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - |
| FCF growth (YoY) | -53.6% | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - |
| Book value growth (YoY) | 21.1% | -15.8% | - | - | - | - | - |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing BioAge Labs against the 5 most active filers in the same SIC group.